Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Susan O’Brien, Richard R. Furman et al.|New England Journal of Medicine|2013Cited by 2.2k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Jesse McGreivy et al.|New England Journal of Medicine|2015Cited by 890
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|The Lancet Oncology|2017Cited by 378
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, John F. Seymour, Michael Hallek et al.|Clinical Cancer Research|2018Cited by 161
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemiaBing Cui, Thomas J. Kipps, Emanuela M. Ghia et al.|Blood|2016Cited by 144